Drug intelligence / Profile preview

cefalotin

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Intravenous
01

Overview

Cefalotin (also known as cephalothin or sefalothin) is a semisynthetic first-generation cephalosporin antibiotic. It acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. Cefalotin is structurally related to other first-generation cephalosporins such as cefazolin and is administered parenterally (intravenous or intramuscular routes). Its primary indications include the prevention of infections during surgery and the treatment of a broad spectrum of infections including those affecting blood, bone or joints, respiratory tract, skin, and urinary tract[6][8][10]. The drug contains a beta-lactam moiety that makes it susceptible to degradation by beta-lactamases produced by some bacteria[10].

Brand names
KeflinCoaxinAveron-1Averon1Averon 1CemastinSeffin
Other names
cefalotincephalothinsefalothin
02

Targets

PBP1b (Penicillin-binding protein 1B)PBP1A (Penicillin-binding protein 1A)

Beyond the preview

Go deeper on cefalotin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefalotin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call